004310 — Hyundai Pharmaceutical Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual cashflow statement for Hyundai Pharmaceutical Co, fiscal year end - November 30th, KRW millions except per share, conversion factor applied.

	2019 November 30th	2020 November 30th	2021 November 30th	2022 November 30th	2023 November 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS/A	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	1,213	2,187	-3,173	-165	6,122
Depreciation
Amortisation
Non-Cash Items	5,207	2,943	5,364	9,507	17,575
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-4,219	1,562	-1,037	-1,016	-31,542
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	5,714	10,804	5,132	11,624	-4,545
Capital Expenditures	-2,359	-6,401	-6,809	-6,584	-6,104
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-369	-5,987	6,781	-3,407	3,016
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-2,728	-12,388	-27.7	-9,991	-3,088
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-2,943	7,452	3,251	7,005	-6,429
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	42.8	5,868	8,356	8,638	-14,063